News & Events
News & Events
May 31, 2023
CACNA1A Foundation to Contribute Data to C-Path’s RDCA-DAP, Accelerating Neurological Disease Research and Therapeutic DevelopmentTUCSON, Ariz., May 31, 2023 — Critical Path Institute (C-Path) announced today that the CACNA1A Foundation, a parent-led nonprofit organization dedicated to creating awareness and finding a cure for CACNA1A-genetic related disorders, will be contributing data to the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®) managed by C-Path. CACNA1A is a gene that is...
April 25, 2023
C-Path Europe: A Global Vision of SuccessTUCSON, Ariz. and AMSTERDAM, April 26, 2023 — As an organization that generates regulatory-endorsed solutions and methodologies to accelerate drug development, Critical Path Institute (C-Path) today shared a year-in-review of its European-focused activities to advance global regulatory science. “We are pleased with the progress and continued development of our global efforts in the regulatory and...
March 29, 2023
C-Path Appoints Key Scientific Leaders to Executive RolesTUCSON, Ariz., March 29, 2023 — Critical Path Institute (C-Path) announced today the appointment of three accomplished leaders to key executive roles within the organization. Cheryl D. Coon, Ph.D., joins C-Path as the Vice President for the Clinical Outcome Assessment (COA) Program. Shu Chin Ma, Ph.D., M.Sc., M.Phil., EMBA, has been named Vice President of...
February 17, 2023
C-Path Stands with Bruce Willis, Neurodegenerative Disease Community After FTD DiagnosisC-Path and its members stand with Bruce Willis and his family as they bravely revealed the difficult news of his Frontotemporal Degeneration (FTD) diagnosis yesterday. Also known as frontotemporal degeneration, the Association for Frontotemporal Degeneration (AFTD) defines FTD as a group of brain disorders caused by degeneration of the frontal and/or temporal lobes of the...
January 25, 2023
C-Path Receives Letter of Support from EMA on Duchenne Muscular Dystrophy Clinical Trial Simulation Platform
C-Path today announced that the European Medicines Agency (EMA) has issued a letter of support for the Duchenne Regulatory Science Consortium’s (D-RSC) Model-based Clinical Trial Simulation Platform for Duchenne Muscular Dystrophy (DMD).